[HTML][HTML] Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel

…, RE Coleman, R Colomer, L Costa, L Crinò, L Dirix… - Annals of oncology, 2008 - Elsevier
Bisphosphonates (BP) prevent, reduce, and delay cancer-related skeletal complications in
patients, and have substantially decreased the prevalence of such events since their …

[HTML][HTML] 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer

…, T Mok, K O'Byrne, S Novello, L Bubendorf… - Annals of …, 2015 - Elsevier
To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …

[HTML][HTML] The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC

…, M Reck, YL Wu, OT Brustugun, L Crinò… - Journal of Thoracic …, 2017 - Elsevier
Over the past few years, there have been considerable advances in the treatments available
to patients with metastatic or locally advanced NSCLC, particularly those who have …

[HTML][HTML] Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer

…, SN Gettinger, CM Rudin, N Rizvi, L Crinò… - … England Journal of …, 2015 - Mass Medical Soc
Background Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint–inhibitor
antibody, disrupts PD-1–mediated signaling and may restore antitumor immunity. …

[HTML][HTML] Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer

J Brahmer, KL Reckamp, P Baas, L Crinò… - … England Journal of …, 2015 - Mass Medical Soc
Background Patients with advanced squamous-cell non–small-cell lung cancer (NSCLC)
who have disease progression during or after first-line chemotherapy have limited treatment …

[HTML][HTML] Nivolumab versus docetaxel in previously treated patients with advanced non–small-cell lung cancer: two-year outcomes from two randomized, open-label …

…, S Antonia, O Arrieta, J Fayette, L Crinò… - Journal of clinical …, 2017 - ncbi.nlm.nih.gov
… Given significant improvements in OS and improved tolerability compared with docetaxel,
PD-(L)1 agents have become the standard of care for patients with NSCLC with progression …

Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

M Früh, D De Ruysscher, S Popat, L Crinò… - Annals of …, 2013 - annalsofoncology.org
An estimated 1.6 million new lung cancers are diagnosed worldwide each year. The highest
incidence rates in males are observed in Central/Eastern and Southern Europe (57 and 49 …

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

…, L Grinsted, V Zazulina, P Smith, I Smith, L Crinò - The lancet …, 2013 - thelancet.com
Background No targeted therapies are available for KRAS-mutant non-small-cell lung cancer
(NSCLC). Selumetinib is an inhibitor of MEK1/MEK2, downstream of KRAS, with preclinical …

[HTML][HTML] PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

…, L Tornillo, RM Incensati, S Sani, L Crinò… - British journal of …, 2015 - nature.com
Background: Agents targeting programmed death-1 receptor (PD-1) and its ligand (PD-L1)
are showing promising results in non-small-cell lung cancer (NSCLC). It is unknown whether …

Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non–small-cell lung cancer

GV Scagliotti, R Fossati, V Torri, L Crino… - Journal of the …, 2003 - academic.oup.com
Background: Surgery is the primary treatment for patients with stage I, II, or IIIA non–small-cell
lung cancer (NSCLC). However, long-term survival of NSCLC patients after surgery alone …